Title:
INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO
Document Type and Number:
WIPO Patent Application WO/2021/065568
Kind Code:
A1
Abstract:
Among CD20-positive cancers, some develop a resistance to obinutuzumab and some reappear after being treated with the use of obinutuzumab. According to the present invention, against a CD20-positive cancer resistant to obinutuzumab or a CD20-positive cancer reappearing after being treated with the use of obinutuzumab, a type II anti-CD20 antibody is used together with at least one compound selected from the group consisting of prednisolone, doxorubicin, vincristine, salts thereof and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, salts thereof and prodrugs thereof may be selected. Among these compounds, moreover, prednisolone, salts thereof and prodrugs thereof may be selected.
Inventors:
FUJIMURA TAKAAKI (JP)
KASHIMA YORIKO (JP)
KASHIMA YORIKO (JP)
Application Number:
PCT/JP2020/035457
Publication Date:
April 08, 2021
Filing Date:
September 18, 2020
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K39/395; A61K31/475; A61K31/573; A61K31/704; A61P35/00; A61P43/00
Domestic Patent References:
| WO2019017499A2 | 2019-01-24 |
Foreign References:
| JP2011515428A | 2011-05-19 |
Other References:
FUJIMURA, TAKAAKI ET AL.: "The effectiveness of obinutuzumab retreatment in obinutuzumab direct cell death resistant models", ABSTRACTS OF THE 81ST ANNUAL MEETING OF THE JAPANESE SOCIETY OF HEMATOLOGY, September 2019 (2019-09-01), pages S277, XP055813494, Retrieved from the Internet
FUJIMURA, TAKAAKI ET AL.: "The effectiveness of obinutuzumab retreatment in obinutuzumab direct cell death resistant models", ABSTRACT OF THE 81ST ANNUAL MEETING OF THE JAPANESE SOCIETY OF HEMATOLOGY, SESSION INFORMATION, vol. 17, September 2019 (2019-09-01), pages 40 - 18, Retrieved from the Internet
FUJIMURA, T. ET AL.: "The efficacy of obinutuzumab retreatment in obinutuzumab-induced direct cell death resistant CD 20-positive non-hodgkin lymphoma model", HEMASPHERE, vol. 4, no. 1, June 2020 (2020-06-01), pages 62
FUJIMURA, TAKAAKI ET AL.: "The effectiveness of obinutuzumab retreatment in obinutuzumab direct cell death resistant models", ABSTRACT OF THE 81ST ANNUAL MEETING OF THE JAPANESE SOCIETY OF HEMATOLOGY, SESSION INFORMATION, vol. 17, September 2019 (2019-09-01), pages 40 - 18, Retrieved from the Internet
FUJIMURA, T. ET AL.: "The efficacy of obinutuzumab retreatment in obinutuzumab-induced direct cell death resistant CD 20-positive non-hodgkin lymphoma model", HEMASPHERE, vol. 4, no. 1, June 2020 (2020-06-01), pages 62
Attorney, Agent or Firm:
SONODA & KOBAYASHI INTELLECTUAL PROPERTY LAW (JP)
Download PDF: